Chronic Lymphocytic Leukemia | Specialty

Role of Targeted Therapies Evolving in CLL

July 20th 2016

The treatment landscape for patients with chronic lymphocytic leukemia continues to evolve, as long-term data become available from pivotal studies that led to the FDA approvals for the BTK inhibitor ibrutinib (Imbruvica) and the PI3K inhibitor idelalisib (Zydelig).

Dr. Jennifer Brown on the Role of FCR in CLL

July 13th 2016

Dr. Byrd on Alacabrutinib's Mechanism of Action in CLL

July 8th 2016

John Byrd, MD, director of the Division of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Ohio State University Comprehensive Cancer Center, discusses the mechanism of acalabrutinib, a next-generation BTK inhibitor as a potential treatment for patients with chronic lymphocytic leukemia.

Dr. Francesco Forconi on B-cell Receptor Structure and Function in CLL

July 6th 2016

Francesco Forconi, MD, associate professor of Hematology, University of Southampton, United Kingdom, discusses the role of the B-cell receptor (BCR) in chronic lymphocytic leukemia (CLL).

Preliminary Data for Duvelisib in Indolent NHL

June 29th 2016

PI3K-Targeted Therapy for Follicular Lymphoma

June 29th 2016

Treatment of Follicular Lymphoma

June 29th 2016

Encouraging Early Data for Novel PI3K Inhibitors

June 29th 2016

Duvelisib in Relapsed/Refractory CLL

June 29th 2016

Role of PI3K-Targeted Therapy in CLL

June 29th 2016

Treating Chronic Lymphocytic Leukemia

June 29th 2016

B-Cell Receptor Inhibition Paints a Complex Picture in CLL

June 24th 2016

Francesco Forconi, MD, discusses his research into the B-cell receptor structure and its function in chronic lymphocytic leukemia.

Maintenance Ofatumumab for CLL Unlikely to Receive European Approval

June 24th 2016

The EMA’s Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion to ofatumumab regarding its potential use in the maintenance setting for patients with relapsed chronic lymphocytic leukemia.

Dr. John Byrd on Challenges in CLL

June 21st 2016

Ibrutinib Highly Effective for Del17p CLL in Combined Analysis

June 11th 2016

Ibrutinib continued to demonstrate impressive antitumor activity in a pooled analysis of 243 patients with deletion 17p chronic lymphocytic leukemia.

Efforts Continue to Optimize Ibrutinib in CLL

June 2nd 2016

Jennifer Brown, MD, discusses the findings and impact of the RESONATE and RESONATE-2 trials, as well as the role of ibrutinib in older and younger patients with chronic lymphocytic leukemia in both the frontline and relapsed settings.

Expert Sheds Light on Role of Next-Generation Agents in CLL

June 1st 2016

Susan M. O'Brien, MD, discusses upcoming novel treatments in relapsed/refractory chronic lymphocytic leukemia, such as the next generation of inhibition with BTK, SYK, and PI3K, as well as the outcomes of the recent RESONATE-2 trial.

Frontline Ibrutinib Approved in Europe for CLL

June 1st 2016

The European Commission has approved ibrutinib (Imbruvica) as a first-line treatment for patients with chronic lymphocytic leukemia.

Dr. Wierda on Immunotherapy Agents for Patients With CLL

May 31st 2016

William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses immunotherapy agents being explored in patients with chronic lymphocytic leukemia (CLL).

FDA Updates Ibrutinib CLL Label With New OS, Combo Data

May 9th 2016

The FDA has expanded the label of ibrutinib (Imbruvica) to include overall survival results in treatment-naive patients with chronic lymphocytic leukemia, as well as outcomes with the BTK inhibitor when combined with bendamustine and rituximab in relapsed/refractory patients with CLL.